Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Jeremy Bender

Jeremy Bender

Chief Executive Officer, Day One Biopharmaceuticals

Appears in 1 story

Notable Quotes

"Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life-threatening diseases." — Statement on Servier acquisition, March 2026

Stories

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

Money Moves

Leading Day One through Servier acquisition

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the Food and Drug Administration (FDA) cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Now the company behind it, Day One Biopharmaceuticals, has agreed to be acquired by France's Servier for $2.5 billion in cash, a 68% premium over its previous closing share price.

Updated Mar 6